Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
OTCMKTS
· Delayed Price · Currency is USD
32.30
0.00 (0.00%)
May 9, 2025, 4:00 PM EDT
HTSUF Revenue
In the fiscal year ending February 28, 2025, Hisamitsu Pharmaceutical Co. had annual revenue of 156.01B JPY with 10.09% growth. Hisamitsu Pharmaceutical Co. had revenue of 44.75B in the quarter ending February 28, 2025, with 15.11% growth.
Revenue
156.01B JPY
Revenue Growth
+10.09%
P/S Ratio
2.11
Revenue / Employee
56.54M JPY
Employees
2,759
Market Cap
2.19B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Feb 28, 2025 | 156.01B | 14.30B | 10.09% |
| Feb 29, 2024 | 141.71B | 13.38B | 10.42% |
| Feb 28, 2023 | 128.33B | 8.14B | 6.77% |
| Feb 28, 2022 | 120.19B | 5.68B | 4.96% |
| Feb 28, 2021 | 114.51B | -26.48B | -18.78% |
| Feb 29, 2020 | Pro | Pro | Pro |
| Feb 28, 2019 | Pro | Pro | Pro |
| Feb 28, 2018 | Pro | Pro | Pro |
| Feb 28, 2017 | Pro | Pro | Pro |
| Feb 29, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |